United States

Prima BioMed Ltd (PRR.AX)

PRR.AX on Australia Stock Exchange

21 Sep 2017
Change (% chg)

$0.00 (+4.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activa... (more)
No analyst recommendations are available for .


Beta: 0.40
Market Cap(Mil.): $49.53
Shares Outstanding(Mil.): 2,358.36
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Prima Biomed Prima secures Japanese patent grant for IMP731 antibody

* Prima secures Japanese patent grant for imp731 antibody Source text for Eikon: Further company coverage:

Sep 08 2017

BRIEF-Prima BioMed announces second milestone payment for IMP701 program

* it will receive a second undisclosed significant clinical milestone payment from Novartis

Jul 16 2017

BRIEF-Prima Biomed ‍received approval for intiation of ‘Insight’ clinical trial

* Received regulatory and ethical approvals for clinical trial investigating IMP321 in new settings, called Insight​

Jul 09 2017

BRIEF-Prima Biomed enters securities purchase agreement to purchase 2.6 mln of its American Depositary shares

* Entered into a securities purchase agreement with certain accredited investors to purchase 2.6 million of its american depositary shares

Jun 29 2017

BRIEF-Prima Biomed announces pricing of direct offering of its American Depositary Shares

* Prima Biomed Ltd announces pricing of $5.0 million registered direct offering of its American depositary shares

Jun 29 2017

Earnings vs. Estimates